JP2022525779A - ６，８－ビス－ベンジルチオ－オクタン酸を使用してリンパ腫を治療するため治療方法および組成物 - Google Patents

６，８－ビス－ベンジルチオ－オクタン酸を使用してリンパ腫を治療するため治療方法および組成物 Download PDF

Info

Publication number
JP2022525779A
JP2022525779A JP2021556419A JP2021556419A JP2022525779A JP 2022525779 A JP2022525779 A JP 2022525779A JP 2021556419 A JP2021556419 A JP 2021556419A JP 2021556419 A JP2021556419 A JP 2021556419A JP 2022525779 A JP2022525779 A JP 2022525779A
Authority
JP
Japan
Prior art keywords
administered
lymphoma
benzylthio
bis
octanoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525779A5 (https=
Inventor
エス パーディー，ティモシー
エーデルソン，ジェフリー
ノイ，アリエラ
ラマー，ザネッタ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wake Forest University Health Sciences
Original Assignee
Wake Forest University Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wake Forest University Health Sciences filed Critical Wake Forest University Health Sciences
Publication of JP2022525779A publication Critical patent/JP2022525779A/ja
Publication of JP2022525779A5 publication Critical patent/JP2022525779A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021556419A 2019-03-19 2020-03-19 ６，８－ビス－ベンジルチオ－オクタン酸を使用してリンパ腫を治療するため治療方法および組成物 Pending JP2022525779A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962820767P 2019-03-19 2019-03-19
US62/820,767 2019-03-19
PCT/US2020/023537 WO2020191144A1 (en) 2019-03-19 2020-03-19 Therapeutic methods and compositions for treating lymphoma using 6,8-bis-benzylthio-octanoic acid

Publications (2)

Publication Number Publication Date
JP2022525779A true JP2022525779A (ja) 2022-05-19
JP2022525779A5 JP2022525779A5 (https=) 2023-12-19

Family

ID=72519349

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556419A Pending JP2022525779A (ja) 2019-03-19 2020-03-19 ６，８－ビス－ベンジルチオ－オクタン酸を使用してリンパ腫を治療するため治療方法および組成物

Country Status (11)

Country Link
US (1) US20220151994A1 (https=)
EP (1) EP3941453A4 (https=)
JP (1) JP2022525779A (https=)
KR (1) KR20220018959A (https=)
CN (1) CN114040758A (https=)
AU (1) AU2020240091A1 (https=)
BR (1) BR112021018138A2 (https=)
CA (1) CA3133101A1 (https=)
MX (1) MX2021011250A (https=)
TW (1) TW202102211A (https=)
WO (1) WO2020191144A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121645A1 (en) * 2018-12-20 2020-06-25 Rafael Pharmaceuticals, Inc. Oral therapy using 6,8-bis-benzylthio-octanoic acid

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263653B2 (en) * 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZANETTA S. LAMAR ET AL., BLOOD, vol. 128, no. 22, JPN6024011050, 2016, pages 4163, ISSN: 0005442397 *

Also Published As

Publication number Publication date
KR20220018959A (ko) 2022-02-15
WO2020191144A1 (en) 2020-09-24
AU2020240091A1 (en) 2021-09-30
EP3941453A4 (en) 2022-12-28
CA3133101A1 (en) 2020-09-24
BR112021018138A2 (pt) 2021-11-16
TW202102211A (zh) 2021-01-16
MX2021011250A (es) 2022-02-11
US20220151994A1 (en) 2022-05-19
EP3941453A1 (en) 2022-01-26
CN114040758A (zh) 2022-02-11

Similar Documents

Publication Publication Date Title
JP6769687B1 (ja) 皮下ｈｅｒ２抗体製剤
JP6706369B2 (ja) 骨髄腫の治療
US20200281921A1 (en) Cancer treatment with combination of plinabulin and taxane
US20230348615A1 (en) Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
US20230250174A1 (en) Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Lenalidomide and Dexamethasone
US20230277660A1 (en) Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone
US20230295333A1 (en) Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone
US20230330224A1 (en) Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone
US20230181534A1 (en) Use of a proteasome inhibitor for the treatment of central nervous system (cns) cancers
JP2022532356A (ja) 抗ｃｄ３８抗体を投与して多発性骨髄腫を処置する方法
JP2022525779A (ja) ６，８－ビス－ベンジルチオ－オクタン酸を使用してリンパ腫を治療するため治療方法および組成物
JP2018516890A (ja) がん治療のためのカバジタキセルおよびその使用
WO2025209479A1 (en) Methods of treatment of immune thrombocytopenia using sovleplenib
US20230295339A1 (en) Method for treating a gd2-positive cancer
Husieva et al. Drug classification for the treatment of hematologic malignancies
Yamazaki et al. Hirohiko Shibayama, Morio Matsumoto, Hiroshi Kosugi, Kazuhiro Shibayama
US20240016805A1 (en) Therapeutic methods and compositions for treating pancreatic cancer using devimistat
JP2022510258A (ja) デビミスタットを使用して急性骨髄性白血病を治療するための治療方法および組成物
TW201540296A (zh) 使用卡巴利他賽（ｃａｂａｚｉｔａｘｅl）於患有晚期胃腺癌且於先前化療療程已失敗的病患之用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240326

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241022